FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition

The protein kinases IKKε and TBK1 are activated in liver and fat in mouse models of obesity. We have previously demonstrated that treatment with the IKKε/TBK1 inhibitor amlexanox produces weight loss and relieves insulin resistance in obese animals and patients. While amlexanox treatment caused a tr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Invest
Hlavní autoři: Reilly, Shannon M., Abu-Odeh, Mohammad, Ameka, Magdalene, DeLuca, Julia H., Naber, Meghan C., Dadpey, Benyamin, Ebadat, Nima, Gomez, Andrew V., Peng, Xiaoling, Poirier, BreAnne, Walk, Elyse, Potthoff, Matthew J., Saltiel, Alan R.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2021
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8121507/
https://ncbi.nlm.nih.gov/pubmed/33822771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI145546
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky